


China promotes development of new cell therapeutic drugs

16 September 2022 | News

Biocytogen collaborates with Finelmmune to develop TCR-mimic antibody-based cell therapy



China-based Biocytogen Pharmaceuticals has collaborated with FineImmune Biotechnology to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.

Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using Finelmmune's unique cell therapy platform.

Biocytogen's TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMice (RenMab and RenLite mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.

FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and *in vivo* T-cell delivery platform (TDP). FineImmune's product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.